MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company
The peer-reviewed Annals of Plastic Surgery, Volume 78, Supplement 1, February 2017, can be found on line at http://journals.lww.com/annalsplasticsurgery/toc/2017/02001, and the hard copy will be available on February 23, 2017.
The Company-sponsored supplement entitled "The Evolution of Burn Injury Management: Using Dehydrated Human Amnion/Chorion Membrane Allografts in Clinical Practice" includes an introduction by Paul M. Glat, MD, referencing MiMedx EpiFix®, EpiBurn® and AmnioFix®. Dr. Glat states that the ability of EpiFix, EpiBurn and AmnioFix to aid in the regeneration and healing of many different tissue types has become apparent in the medical community; that scientific investigation has shown these dehydrated human amnion/chorion membrane allografts contain growth factors and cytokines, including immunomodulatory chemokines, immunomodulatory cytokines, and tissue growth promoting factors; and that angiogenic growth factors retaining biologic activity are also present and studies have shown the potential of these matrices to attract stem cells to the area of the wound.
Highlights of the Peer-Reviewed Articles:The highlights of the peer-reviewed articles published in the Annals of Plastic Surgery supplement are as follows:
Parker H. Petit, Chairman and CEO, stated, "The body of evidence demonstrating the clinical and cost effectiveness of our dHACM allografts and the body of research confirming the scientific foundation and properties of our dHACM allografts is rapidly expanding. The Company's proprietary and patented PURION® Process and strict processing standards and validations that we have developed enable our dHACM allografts to deliver superb clinical outcomes for healing, modulating inflammation and reducing scar tissue formation. We are gratified that so many renowned physicians in the burn management and reconstructive surgery specialties of the industry have such high esteem for the effectiveness of our products."
"This sponsored supplement with peer-reviewed articles authored by numerous prominent physicians is a wonderful complement to our compendium of peer-reviewed published studies. Our compendium has now grown to more than 30 peer-reviewed study articles, including four Randomized Control Trials (RCTs), scientific studies and significant case studies. We are very excited about the opportunities that are available in the burn management and plastic and reconstructive surgery sector of the market," added Bill Taylor, President and COO.
About MiMedxMiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the Company's processing standards and validations enable its dHACM allografts to deliver superb clinical outcomes, and the opportunities available in the burn management and plastic and reconstructive surgery market sector. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company's allografts may not continue to deliver superb clinical outcomes or other products may deliver better outcomes, the esteem for the effectiveness of the Company's products by physicians in the burn management and reconstructive surgery specialties may diminish, the opportunities in the burn management and plastic and reconstructive surgery market sector may not materialize or be as expected, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2015, and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/benefits-of-mimedx-dhacm-allograft-chronicled-in-multiple-articles-in-february-2017-supplement-edition-of-annals-of-plastic-surgery-300403417.html
SOURCE MiMedx Group, Inc.
Subscribe to our Free Newsletters!
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...
Our kitchen and food has the best medicinal properties to fight stress. These are the top 10 foods ...View All